Diabetes & Endocrinology
Spinal cord stimulation eased painful diabetic neuropathy and improved sensation over six months
A blinded-assessment trial adds sensory and nerve-fibre gains to the pain relief already shown; diabetes still carries excess risk after imaging-guided PCI; and empagliflozin shows an early natriuretic signal in refractory cirrhotic ascites.
Semaglutide cut hsCRP by about 38% in SELECT, weeks before the weight came off
A prespecified SELECT analysis links part of semaglutide's cardiovascular benefit to lower inflammation; TrialNet shows stimulated beta-cell function sorts single-autoantibody relatives by risk; and an EHR prompt multiplied diabetes education referrals roughly tenfold.
A Charcot foot diagnosis carries a one-in-three five-year mortality
In a Glasgow registry, most people with Charcot neuro-osteoarthropathy were admitted and fewer than half were alive without amputation at five years; after PCI in diabetes, clopidogrel beat aspirin as long-term monotherapy; and CGM picks up cardiometabolic risk that HbA1c misses.
Semaglutide response cannot be predicted at baseline — dose and time decide it
In 7,594 SELECT participants, baseline characteristics explained under 10% of peak weight loss. Also: orforglipron dose comparison, PMOS as a pregnancy risk marker, CGM trajectories in type 1, and weekly ketone checks.
With a GLP-1 agonist on board, oxycodone carries about half again the bowel risk of hydrocodone or tramadol
A 411,000-patient claims cohort puts numbers on an interaction most prescribers only suspect. Also: lifestyle treatment in PMOS pooled across 34 studies, waist beats BMI for spotting diabetes in 82 low- and middle-income countries, insulin sensitivity across the menstrual cycle on closed loop, and tirzepatide's arrhythmia signal.
SGLT2 ketoacidosis risk lasts the whole course, not the first month
A 282,000-patient Scandinavian register study finds ketoacidosis on SGLT2 inhibitors clusters in identifiable patients and persists throughout treatment. Also: the 2026 ADA/EASD type 1 consensus, supervised exercise in pregnancy, glargine versus NPH in low-resource settings, and a Baxter insulin infusion recall.
Below-knee amputation carries a 23.5% one-year mortality that has not moved since 2012
An England population study of 25,176 people with diabetes reframes what a major amputation means, a new insulin aspart product reaches the US market, and three societies agree how young adults should be handed over.
Empagliflozin's benefit holds across every subgroup Medicare could slice
A real-world analysis finds no sociodemographic group left behind by SGLT2 inhibition, a Swedish register quantifies what early-onset type 1 diabetes costs over a lifetime, and the risks of stopping an incretin come into focus.
A dual agonist pushes weight loss past 18%, and neuropathy gets an objective signal
Mazdutide's phase 2 numbers land at the top of the incretin range; a spinal cord stimulation trial reports nerve fibre density, not just pain scores; and glucose variability earns another look as a vascular risk marker.
GLP-1 receptor agonists: the renal signal is now the larger one
A 20-trial, 83,004-patient meta-analysis puts numbers on cardiovascular and kidney protection in type 2 diabetes; a roadmap argues SGLT inhibitors should finally be trialled properly in type 1; and an EHR prompt lifts self-management referrals tenfold.
Technology guidance widens, and two trials test what the numbers really mean
AACE sets out where continuous glucose monitoring and automated insulin delivery now belong in adult care; SELECT suggests semaglutide's cardiovascular benefit is partly anti-inflammatory; and a stopped immunotherapy shows how quickly a preserved beta cell is lost again.
Orforglipron's higher maintenance dose earns its place — and India's price falls change who can be offered a GLP-1
A six-trial meta-analysis separates the 12 mg and 36 mg maintenance doses of oral orforglipron; a policy analysis puts numbers on what generic competition has done to SGLT2 inhibitor and GLP-1 prices in India; a compounder's semaglutide vials are recalled for particulate matter; and weekly ketone testing looks enough to stratify DKA risk.
On a GLP-1 agonist and needing an opioid: oxycodone carried the most bowel trouble
A 411,000-patient claims cohort compares opioids in GLP-1RA users, compounded semaglutide vials are recalled for particulate matter, and waist circumference beats BMI at spotting diabetes in 82 low- and middle-income countries.
SGLT2 inhibitor ketoacidosis risk does not fade after the first months
A 282,000-patient Scandinavian register study finds the risk persists through treatment and clusters in identifiable patients. Also: the 2026 ADA/EASD type 1 consensus, a Baxter insulin recall, and glargine versus human insulin in low-resource settings.
Below-knee amputation in diabetes: 23.5% dead at one year, and no better than 2012
A 25-year England population study puts hard numbers on what a major amputation means. Plus a Class II recall of compounded semaglutide, and a three-society consensus on moving young people to adult services.
One in five patients with pulmonary fibrosis has diabetes, and a recall that is about the vial rather than the drug
A quiet desk today. The substantial finding is a 606,000-patient synthesis putting real prevalence figures on the metabolic comorbidity of idiopathic pulmonary fibrosis - consistently higher than the trial cohorts suggested.
Spinal cord stimulation improved sensation, not just pain, in diabetic neuropathy
A randomised trial of 10-kHz spinal cord stimulation for painful diabetic neuropathy reported blinded gains in sensory score and nerve fibre density alongside pain relief. Plus glycaemic variability and peripheral artery disease, a consensus on bone fragility in diabetes, diabetes-specific tube feeds, and a Class II recall of compounded semaglutide.
What "in range" feels like, and who automated insulin delivery actually helps
Guideline range and lived experience pull apart on blinded CGM; BMI normalisation tracks slower progression in autoantibody-positive youth; and eighteen months of AID data show who plateaus.
Metformin lowers rifampicin exposure by a quarter
A pharmacokinetic substudy in HIV-associated tuberculosis found bioavailability of rifampicin and isoniazid fell on metformin — a problem wherever both diseases are common. Plus updated US consensus on diabetes technology, a licence supplement for a triple oral combination, thirty years of adolescent complication trends, and 24-hour urine sodium against diabetes risk.
Muscle and fat together predict diabetes better than either alone
In 479,607 UK Biobank participants, sarcopenic obesity carried three and a half times the risk of type 2 diabetes — and moving into that phenotype carried it too. Plus compounded semaglutide vials recalled for particulate matter, a vaccine trial in severe obesity, what depression adds to diabetes outcomes, and how badly Charcot foot ends.
Surgery still beats the injection on the cardiovascular endpoints
A network meta-analysis of 932,000 patients finds bariatric surgery reduces MACE, heart failure and myocardial infarction while GLP-1 receptor agonists move only MACE. Also: insulin sensitivity swings with the menstrual cycle even under closed-loop control, a compounded semaglutide recall for particulate matter, and why the opioid you choose matters in a patient already on a GLP-1.
Once a week is enough for the ketone strip
A modelling study on 1410 trial participants says weekly well-day ketone testing predicts a month's ketoacidosis risk as well as twice-weekly does; 179 of 180 ketoacidosis events in DCCT happened after C-peptide had gone; and compounded semaglutide vials are being recalled for particulate matter.
Glargine gave children in low-resource settings no advantage over human insulin
A randomised trial in Bangladesh and Tanzania found insulin glargine no better than human isophane on either co-primary glycaemic outcome, a Bayesian re-analysis put half the weight lost on semaglutide or tirzepatide back within seven and a half months of stopping, and 48 trials found no signal of gastrointestinal cancer with SGLT2 inhibitors.
Analogue insulin gives no glycaemic edge over human insulin in low-resource settings
A randomised trial in Bangladesh and Tanzania found glargine no better than isophane insulin for time in range or serious hypoglycaemia in young people with type 1 diabetes. Plus: who actually gets ketoacidosis on an SGLT2 inhibitor, and metformin fails to prevent gestational diabetes.
Ketoacidosis on SGLT2 inhibitors never stops being a risk
Scandinavian registry data show DKA risk on SGLT2 inhibitors persists well beyond the first weeks, glargine fails to beat human insulin in low-resource paediatric type 1 diabetes, and weight comes back fast after incretins stop.